Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Nina E. Weisser"'
Autor:
Nina E. Weisser, Mario Sanches, Eric Escobar-Cabrera, Jason O’Toole, Elizabeth Whalen, Peter W. Y. Chan, Grant Wickman, Libin Abraham, Kate Choi, Bryant Harbourne, Antonios Samiotakis, Andrea Hernández Rojas, Gesa Volkers, Jodi Wong, Claire E. Atkinson, Jason Baardsnes, Liam J. Worrall, Duncan Browman, Emma E. Smith, Priya Baichoo, Chi Wing Cheng, Joy Guedia, Sohyeong Kang, Abhishek Mukhopadhyay, Lisa Newhook, Anders Ohrn, Prajwal Raghunatha, Matteo Zago-Schmitt, Joseph D. Schrag, Joel Smith, Patricia Zwierzchowski, Joshua M. Scurll, Vincent Fung, Sonia Black, Natalie C. J. Strynadka, Michael R. Gold, Leonard G. Presta, Gordon Ng, Surjit Dixit
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-22 (2023)
The success of HER2-targeted cancer therapy is limited by treatment resistance. Here, the authors engineer an anti-HER2 biparatopic antibody with multiple mechanisms of action including induction of HER2 clustering to trigger complement dependent cyt
Externí odkaz:
https://doaj.org/article/8a871ad93e594eeba832492229b1329b
Autor:
Maya C. Poffenberger, Meghan M. Verstraete, Anna Von Rossum, Patricia Zwierzchowski, Matteo Zago, Veronica Luu, Sifa Arrafi, Siran Cao, Harsh Pratap, Chayne L. Piscitelli, Nina E. Weisser, Thomas Spreter von Kreudenstein
Publikováno v:
Cancer Research. 83:2982-2982
CD3-bispecific T cell engager (TCE) therapies have exhibited clinical utility against hematological malignancies, but successes in solid tumor indications have been limited. Compared to heme malignancies, treatment of solid tumors is hindered by immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5973d138d8e10d3f7bfbf1b4779ae8d
https://doi.org/10.1158/1538-7445.am2023-2982
https://doi.org/10.1158/1538-7445.am2023-2982
Autor:
Nicole J. Afacan, Chayne Piscitelli, Patricia Zwierzchowski, Siran Cao, Janessa Li, Wingkie Wong, Kara White-Moyes, Thomas Spreter von Kreudenstein, Nina E. Weisser
Publikováno v:
Cancer Research. 83:2942-2942
Mesothelin (MSLN) is a GPI-linked membrane glycoprotein that is overexpressed in many cancer indications for which there is a high unmet medical need including pancreatic, mesothelioma, and ovarian. While MSLN-targeting agents have shown early signs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47ca053e06e44685c44c41a369db68b8
https://doi.org/10.1158/1538-7445.am2023-2942
https://doi.org/10.1158/1538-7445.am2023-2942
Autor:
Lisa Newhook, Purva P. Bhojane, Peter W. Repenning, Diego Perez Escanda, Nichole K. Escalante, Patricia Zwierzchowski, Alec Robinson, Lauren Clifford, Harsh Pratap, David N. Douda, Chayne L. Piscitelli, Nicole J. Afacan, Thomas Spreter von Kreudenstein, Nina E. Weisser
Publikováno v:
Cancer Research. 83:5121-5121
Bispecific T cell engager (TCE) therapies have exhibited clinical utility against hematological cancers, but limited success in solid tumors. Treatment of solid tumors has additional challenges - including immunosuppressive environments and low T cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce0b30ab0d4c4263c81cb50f1010c356
https://doi.org/10.1158/1538-7445.am2023-5121
https://doi.org/10.1158/1538-7445.am2023-5121
Autor:
Grant Wickman, Sam Lawn, Joe Schrag, Gordon Yiu Kon Ng, Nina E. Weisser, David Kai Yuen Poon, Mario Sanches, Maria L. Jaramillo, Jason Baardsnes, Mauro Acchione, Igor Edmondo Paolo D'angelo, John C. Zwaagstra, Ian Schoenhofen, Surjit Bhimarao Dixit
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest. Antibodies have dominated this field as the pref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9914dffa3f6bcd78d30b1982a9e2e0f
https://doi.org/10.1080/19420862.2020.1802188
https://doi.org/10.1080/19420862.2020.1802188
Autor:
Bryant T. Harbourne, Jason O'Toole, Chi Wing Cheng, Gerry Rowse, Peter Wing Yiu Chan, Neil Josephson, Browman Duncan, Nina E. Weisser, Grant Raymond Wickman, Libin Abraham, Michael R. Gold, Joy Guedia, Surjit Bhimarao Dixit
Publikováno v:
Cancer Research. 81:1005-1005
HER2-directed therapies have improved clinical outcomes for many patients with HER2-positive breast and gastric cancer. Despite these successes, there remains a need to develop improved HER2-targeted therapies for these and other HER2-expressing tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e4525958fca51a8cfb4208f92477748
https://doi.org/10.1158/1538-7445.am2021-1005
https://doi.org/10.1158/1538-7445.am2021-1005
Publikováno v:
Cancer Research. 77:31-31
HER2-directed therapies have improved clinical outcomes for many patients with HER2 overexpressing breast and gastric cancer. Despite these successes, there remains a need to develop effective HER2-targeted therapies for these and other HER2-expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b96b52509afbaf27257d7c8677f54ae
https://doi.org/10.1158/1538-7445.am2017-31
https://doi.org/10.1158/1538-7445.am2017-31
A self-consistent model of beta-mannan oligosaccharides bound to a monoclonal antibody, C3.1, that protects mice against Candida albicans has been developed through chemical mapping, NMR spectroscopic, and computational studies. This antibody optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75a1e775cb55b4e43574ed681dd0110
http://hdl.handle.net/10379/12099
http://hdl.handle.net/10379/12099
Publikováno v:
Molecular immunology. 47(7-8)
The use of recombinant antibody fragments (rAbF) as therapeutic agents is compromised by shorter serum persistences than IgG therapeutics and their inability to mediate Fc-dependent effector functions. Here, we show that the strategy of complex forma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aecf2d766975d91194b70133ac6734b
https://pubmed.ncbi.nlm.nih.gov/20153529
https://pubmed.ncbi.nlm.nih.gov/20153529
Autor:
J. Christopher Hall, Nina E. Weisser
Publikováno v:
Biotechnology advances. 27(4)
Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody (rAb) fragments are becoming popular therapeutic alternatives to full
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c2613670401ba7ba198257b58ae12e6
https://pubmed.ncbi.nlm.nih.gov/19374944
https://pubmed.ncbi.nlm.nih.gov/19374944